Bausch Health Companies Inc.

BHC

CA0717341071

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:01 2024-05-10 pm EDT			5-day change	1st Jan Change
6.88 ^USD	-1.01%		-12.02%	-14.21%

May. 03	RBC Lowers Bausch Health Target to US$10, Maintains Sector Perform	MT
May. 02	Bausch Health Shares Fall Following Q1 Results	MT

Bausch Health Companies Inc. Provides Revenue Guidance for the Year Full Year 2022

May 10, 2022 at 06:59 am EDT

Bausch Health Companies Inc. provided revenue guidance for the year full year 2022. For the period, full-Year revenue range of $8.25 billion – $8.40 billion, reaffirming organic growth of 3% – 5%.

Latest news about Bausch Health Companies Inc.

RBC Lowers Bausch Health Target to US$10, Maintains Sector Perform	May. 03	MT
Bausch Health Shares Fall Following Q1 Results	May. 02	MT
Bausch Health Q1 Net Loss Narrows on Higher Revenue, Confirms 2024 Revenue Guidance	May. 02	MT
Transcript : Bausch Health Companies Inc., Q1 2024 Earnings Call, May 02, 2024	May. 02
Bausch Health Brief: Reaffirmed full-year Revenue and Adjusted EBITDA (non-GAAP) guidance	May. 02	MT
Bausch Health Brief: Q1 revenues of US$2.15 billion, up 11% on a Reported and 8% on an Organic basis	May. 02	MT
Bausch Health Companies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
North American Morning Briefing : Stock Futures -2-	May. 02	DJ
Needham Says Bausch + Lomb's Q1 Showed a "Strong Start" to The Year	May. 01	MT
Bausch + Lomb Brief: Raising Full-Year 2024 Constant Currency Revenue Growth Guidance	May. 01	MT
Bausch + Lomb Brief: Q1 Adjusted EBITDA (non-GAAP) of US$180 Million	May. 01	MT
Bausch + Lomb Brief: Q1 Revenue of US$1.099 Billion; GAAP Net Loss Attributable of $167 Million	May. 01	MT
Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes	Apr. 25	MT
Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	Apr. 25	MT
Bausch Health in 'Stronger Position' for Bausch + Lomb Distribution, RBC Says	Apr. 23	MT
RBC Previews Bausch Health's Q1, Trims Target to US$11	Apr. 23	MT
RBC Trims Price Target on Bausch Health to $11 From $12, Keeps Sector Perform Rating	Apr. 23	MT
RBC Cuts Bausch + Lomb Target to US$18, Reiterates Outperform, as Previews Q1	Apr. 22	MT
Bausch Health's Issuer Credit Rating Upgraded by S&P	Apr. 19	MT
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says	Apr. 12	MT
RBC Notes "Positive" Appellate Court Ruling For Bausch Health, But Thinks Market Assigning ~32% BLCO Distribution Odds	Apr. 12	MT
Bausch wins US appeal to block Alvogen generic of diarrhea drug	Apr. 11	RE
Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan	Apr. 11	CI
TSX ends flat as gold stocks drop, mood cautious ahead of rate decision	Apr. 08	RE
Bausch Health Up Near 0.4% In US Premarket After Announcing Patent Lawsuit Against Amneal Pharmaceuticals	Apr. 08	MT

Chart Bausch Health Companies Inc.

Duration

Period

More charts

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

Sector

Pharmaceuticals

Calendar

2024-05-14 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Bausch Health Companies Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

6.88 USD

Average target price

9.786 USD

Spread / Average Target

+42.23%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAUSCH HEALTH COMPANIES INC.	-14.21%	2.52B
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals